RadNet to increase AI presence with acquisition of DeepHealth

RadNet, one of the largest radiology providers in the United States, has entered into a definitive agreement to acquire DeepHealth, an imaging technology company focused on using AI to improve breast cancer screening.  

The deal is expected to be finalized on April 1, when RadNet will make an initial payment of 1 million shares of stock. Additional payments will occur if specific milestones—FDA approval for key algorithms, for example—are met.

Gregory Sorenson, MD, co-founder and president of DeepHealth, will lead RadNet’s AI operations once the acquisition is complete. Sorenson, a board-certified neuroradiologist, will also continue managing DeepHealth staff moving forward.

“We are more certain today than ever before that artificial intelligence will transform the diagnostic imaging and radiology industry,” Howard Berger, MD, chairman and CEO of RadNet, said in a prepared statement. “Machine learning, big data applications and automation algorithms will allow us to deliver our services more cost effectively, efficiently and accurately. We have been tracking DeepHealth’s progress and evaluating its algorithms for some time. Not only do we believe Greg and his talented team of developers and computer scientists are leading the field in AI solutions for mammography, but DeepHealth’s core competencies and human resources are the perfect combination to direct other important RadNet AI initiatives.”

“My team and I are thrilled to join the RadNet family,” Sorenson said in the same statement. “RadNet is unique in the imaging business and positions us to be successful in our mission to create industry-leading AI products and services that have significant impact on patients’ lives.”

Back in August 2019, RadNet launched its new AI division. The company partnered with Whiterabbit.ai in November 2019 to boost mammography screening rates and provide better patient care.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup